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Abstract: Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV
(PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population.
In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among
PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens
as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of
liposomal amphotericin for induction therapy in severe or moderately severe disease, followed by
a maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be
considered if the patient is clinically stable and if immune status has improved; (3) antiretroviral
therapy initiation as soon as possible among patients with histoplasmosis without involvement
of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis and
tuberculosis (TB), treatment of TB should be initiated according to the World Health Organization
treatment guidelines. Appropriate health education of providers, supportive supervision, and policy
guidance for the care of PLHIV are required.
Keywords: advanced HIV disease; diagnosis; histoplasmosis; Histoplasma; guidelines; World Health
Organization (WHO); Pan American Health Organization (PAHO)
1. Introduction
Opportunistic infections such as tuberculosis (TB) and severe bacterial, fungal, and
parasitic infections are the most frequent causes of death among adults with advanced
HIV disease [1,2]. Histoplasmosis caused by the fungus Histoplasma capsulatum has been
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frequently reported in the American continent, where an estimated 15,000 new infec-
tions and 9000 deaths occur among people living with HIV (PLHIV); it is also diagnosed
in much of the world and presumed to be underdiagnosed in most settings [3–5]. Dis-
seminated histoplasmosis (DH), the most frequent clinical presentation of this disease
among PLHIV, remains challenging due the non-specificity of symptoms from other infec-
tious diseases, in particular TB, and the limited access to specific diagnostic assays and
treatment [6–8]. As disseminated histoplasmosis is associated with high mortality rates
due to late diagnosis [9,10], rapid detection of histoplasmosis and specific treatment are
needed [9,11,12]. The development of a novel histoplasmosis diagnostic assay and its recent
inclusion in the WHO list of Essential Diagnostics as well as the inclusion of new effective
antifungal agents in the Essential Medicine List, generate new opportunities for improving
the management and care of PLHIV having disseminated histoplasmosis [13–15]. This
review summarizes the recently published World Health Organization (WHO)/Pan Ameri-
can Health Organization (PAHO) guidelines for diagnosing and managing disseminated
histoplasmosis among PLHIV [16].
2. Materials and Methods
Following WHO processes for guideline development [17], the PAHO/WHO secre-
tariat established a guideline development group (GDG) that included individuals with
recognized expertise in the histoplasmosis field. The group was chaired by an expert in the
management of histoplasmosis with support from a guideline methodologist. In order to
develop systematic reviews and guidelines recommendations, PICO (Patient–Intervention–
Comparison–Outcome) questions were proposed (Figure 1).
Figure 1. Summary of judgment of questions proposed for the development of the guidelines for
diagnosing and managing disseminated histoplasmosis among people living with HIV.
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Systematic reviews were conducted to summarize the evidence relevant to these
questions, and the key findings are summarized in the final guidelines [16]. The Grading
of Recommendations, Assessment, Development, and Evaluation (GRADE) method was
applied to assess the certainty of the evidence as well as to determine the strength of the
recommendations [18]. Additional considerations included feasibility, acceptability, supply
use and cost implications of implementing the recommendations, and clinical outcomes
(such as drug resistance and drug toxicity).
A SWOT (strengths, weaknesses, opportunities, and threats) analysis was conducted.
This analysis focused on the following: (1) access to rapid diagnostic assays, (2) access to
specific antifungal therapy, and (3) surveillance of HIV-associated histoplasmosis (focusing
on morbidity and mortality) [7]. Prior to finalization, the draft guideline was reviewed by
an external peer review group.
3. Results
The judgments made by the guideline development group for each intervention are
summarized in Figure 1.
3.1. Diagnosis of Histoplasmosis
Recommendation 1. “Among people living with HIV, disseminated histoplasmo-
sis should be diagnosed by detecting circulating Histoplasma antigens” (GRADE classi-
fied this recommendation as conditional with low-certainty evidence).
A systematic review and meta-analysis compared the accuracy of different diagnostics
assays for the detection of histoplasmosis in PLHIV [6]. In this meta-analysis, antigen
detection assays showed the highest performance to detect histoplasmosis in PLHIV
(pooled sensitivity, 95%, and pooled specificity, 97%) [6,16]. Advantages of this assay
include its commercial availability and the ability to be implemented in a laboratory with
lower-level biosecurity (levels 1 and 2).
The GDG recommended complementary testing using microscopic analysis of the
buffy coat, histopathological analysis, culture, and antibody or DNA detection in patients
with clinical forms of histoplasmosis different to the disseminated disease [16,19].
3.2. Treatment of Disseminated Histoplasmosis
Three recommendations address the induction and maintenance therapy for histoplas-
mosis among PLHIV and the clinical stage of the disease (severe or moderately severe and
mild to moderately mild).
Recommendation 2.1A. Induction therapy, for severe or moderately severe dissem-
inated histoplasmosis: “Liposomal amphotericin B, 3.0 mg/kg for two weeks is the pre-
ferred treatment for severe or moderately severe disease” (GRADE classified this recom-
mendation as conditional with very-low-certainty evidence).
Within the systematic review, four studies that provided information about relevant
outcomes for induction therapies were identified. This included one randomized control
trial that compared liposomal and deoxycholate amphotericin B. Compared to deoxycholate
amphotericin B, liposomal amphotericin B may have higher clinical success rates (Relative
Risk [RR] 1.46, 95% confidence interval [CI] 1.01 to 2.11; low-certainty evidence). Compared
to deoxycholate amphotericin B, liposomal amphotericin B has lower rates of nephrotoxicity
(RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77 participants; high-certainty evidence) [20–22].
The GDG also recommended that in resource-constrained settings where liposomal
amphotericin B is not available, deoxycholate amphotericin B (0.7–1.0 mg/kg) should be
used as induction therapy for two weeks in severe or moderately severe DH (conditional
recommendation, very low certainty of evidence) [16,20]. In patients with central nervous
system involvement, extension of induction therapy or increased amphotericin B dosage
could be needed [16].
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Recommendation 2.1B. Treating mild to moderate histoplasmosis: “Itraconazole
200 mg twice daily after a loading dose of 200 mg three times daily for three days”
(GRADE classified this recommendation as conditional with very-low-certainty evidence).
Very-low-certainty evidence was identified to inform comparisons between induction
therapy in mild to moderate disease in the systematic review undertaken. Treatment with
fluconazole achieved poor results in comparison to other azoles in the single-arm trial [16].
No further trials were done as there was no longer sufficient equipoise to justify this. In
conclusion, it was found that triazole drugs present lower efficacy than polyenes among
severely ill people. No randomized trial comparing amphotericin B formulations with
triazole drugs have been undertaken [20,21,23].
Recommendation 2.2. Maintenance therapy: “Itraconazole 200 mg twice daily for
12 months is recommended” (GRADE classified this recommendation as conditional with
very-low-certainty evidence). Less than 12 months of therapy can be considered when
the person is clinically stable, receiving antiretroviral therapy, has suppressed viral
load, and the immune status has improved (GRADE classified this recommendation as
conditional with very-low-certainty evidence).
In regard to maintenance therapy, the systematic review that was undertaken did not
find studies comparing less than 12 months of oral itraconazole or 12 months or greater of
oral itraconazole. One prospective single-arm cohort study followed a cohort of participants
who discontinued antifungal therapy after at least 12 months, providing the participant had
received at least six months of antiretroviral therapy (ART) and had achieved a CD4 count
of 150 cells/µL or greater [22]. There were no relapses in 32 participants who discontinued
therapy after 12 months. A single, retrospective cohort study provided anecdotal evidence
that maintenance therapy could be safely discontinued before 12 months but was at critical
risk of bias [20,24]. The recommendation was therefore based on expert opinion.
3.3. Timing of Antiretroviral Therapy Initiation
Recommendation 3. “Antiretroviral therapy should be initiated as soon as possi-
ble among people with disseminated histoplasmosis for whom central nervous system
involvement is not suspected or proven” (GRADE classified this recommendation as
conditional with very-low-certainty evidence).
Only one randomized clinical trial with 282 participants met the inclusion criteria of
a systematic review of studies comparing outcomes of early versus delayed initiation of
antiretroviral therapy in patients with disseminated histoplasmosis [25]. Of the total num-
ber of participants, 10 had HIV and a presumptive or confirmed diagnosis of disseminated
histoplasmosis. By day 30 of follow-up, one of the seven patients in the early antiretroviral
therapy group and none of the three in the late group died.
Based on this restrictive evidence, the efficacy and safety outcomes of early versus
late initiation of antiretroviral therapy are unknown [16,20,26]. Recommendation is based
on the panel clinical expertise and field reports with regard to the balance between the
substantial risk of dying from another opportunistic infection when delaying ART and the
low incidence of histoplasmosis-associated immune reconstitution inflammatory syndrome
(IRIS) versus morbidity and mortality associated with histoplasmosis-associated IRIS
among PLHIV receiving ART [26]. However, WHO HIV/AIDS guidelines recommend
initiating ART as soon as possible after the diagnosis of HIV (within 7 days) [27]. The
panel also recalled that PLHIV presenting for the first time or those returning to care must
undergo evaluation for opportunistic infections (TB and cryptococcosis), particularly those
affecting the central nervous system, before ART initiation. Immediate ART initiation is
not recommended in PLHIV who have cryptococcal meningitis because of the increased
mortality presumably related with IRIS [27,28].
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3.4. Treatment of Co-Infection with Tuberculosis
Recommendation 4. “People living with HIV with TB and histoplasmosis coin-
fection should receive TB therapy according to WHO treatment guidelines” (GRADE
classified this recommendation as conditional with very-low-certainty evidence).
Two studies, including one case report describing treatment outcomes among patients
coinfected with HIV, tuberculosis, and disseminated histoplasmosis were identified through
a systematic review and showed very limited evidence [29,30]. Risks of Mycobacterium tu-
berculosis resistance and drug–drug interactions of a simultaneous rifampicin–itraconazole
regimen (leading to sub-therapeutic and ineffective itraconazole blood levels and histoplas-
mosis treatment failure) were balanced in the context of existing strong WHO’s guidance on
managing HIV and TB coinfection [16,20]. The recommendation relies on WHO guidance
regarding prompt TB therapy initiation and on the panel’s clinical expertise regarding
alternative options to concomitant antifungal therapy with extending the duration of
amphotericin B induction therapy, or increasing itraconazole daily dosage as well as moni-
toring itraconazole blood levels if available, or considering other azole drugs (posaconazole
or voriconazole) or replacing rifampicin with rifabutin [16]. Strong consideration was also
given to a critical review of potential ART regimen options in the context of concomitant
antifungal and anti-TB therapies in order to make necessary adjustments as recommended
in WHO’s consolidated guidelines on the use of antiretroviral drugs for treating and
preventing HIV infection.
Figure 2 summarizes the guidelines’ recommendations.
Figure 2. Summary of: Pan American Health Organization (PAHO)/World Health Organization
(WHO) guidelines for diagnosing and managing disseminated histoplasmosis among people living
with HIV.
4. Discussion
This review summarizes the evidence and other considerations, supporting the for-
mulation of WHO/PAHO global recommendations for the diagnosis, treatment, and man-
agement of disseminated histoplasmosis and disseminated histoplasmosis–tuberculosis
co-infection among PLHIV. These recommendations have been developed through a public
health approach taking into consideration contexts with limited resources and a high
burden of disease. They are intended for healthcare providers, HIV program managers,
policymakers, and other professionals involved in caring for people who either have or
may be at risk of developing disseminated histoplasmosis. While the highest burden of
histoplasmosis is concentrated in the Americas [4], the recommendations contained within
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these guidelines are applicable globally and adaptable according to the resources and
logistical capabilities.
Early diagnosis and opportune treatment initiation are key to improving mortality
from histoplasmosis; for this reason, it is necessary for countries to give priority access
to high-quality in vitro diagnostics for the rapid detection of Histoplasma antigens [7,11].
Implementing this recommendation infers taking appropriate steps to assure adequate
availability of antigen testing in health services managing advanced HIV disease. There
is a need to apply price negotiation and pooled procurement mechanisms to improve
access, especially where histoplasmosis is highly endemic. Access to optimal antifungal
drugs is of great importance. Optimal antifungal medicines for treating people with
histoplasmosis (conventional and liposomal amphotericin B and itraconazole) are part
of the WHO Model List of Essential Medicines [14]. The cost of treatment is still high,
and these drugs are not widely available in many of the countries with a high burden of
histoplasmosis. Among the interventions to consider improving the access to antifungal
medications for treating histoplasmosis are increased advocacy for drug price reduction
and promoting generic production, national registration of all antifungal drugs, applying
joint regional procurement mechanisms, and developing proper drug forecasting and
monitoring systems. Furthermore, appropriate health education for providers, supportive
supervision, and policy guidance at the national level on managing histoplasmosis among
people living with HIV are required.
The systematic reviews highlighted that overall, the certainty of the evidence for most
outcomes was low or very low in this field. Non-randomized study designs predominate
in this area of research, many of which were compromised by uncontrolled confounding.
This led to the development of a number of priority research recommendations [7]. The
process has offered an opportunity to set a research agenda and thereby accelerate the
development of new and improved diagnostics and optimize program implementation.
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